Dr. Reddy's Laboratories Ltd. Recalls Ranitidine Tablets and Capsules

Date: 10/30/19

On October 23, 2019, the US Food and Drug Administration (FDA) announced that Dr. Reddy’s Laboratories Ltd. was recalling all Ranitidine products with expiration dated September 2019 to June 2021 to the consumer level due to NDMA was found in certain samples of ranitidine.

The FDA press release states the following:

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries, together referred to as “Dr. Reddy’s”) confirms it had initiated a voluntary nationwide recall on October 1, 2019, (at the retail level for over-the-counter products and at the consumer level for prescription products) of all of its Ranitidine medications sold in US due to confirmed contamination with N-Nitrosodimethylamine (NDMA) above levels established by the FDA. This recall follows the USFDA’s caution note alerting patients and health care professionals that NDMA was found in certain samples of ranitidine. To date, Dr. Reddy’s has not received any reports of adverse events related to the recall of Dr. Reddy’s Ranitidine products. The recall includes all quantities in the US that are within expiry.

Review the FDA’s Full Press Release

For questions or concerns, please reach out to Envolve Pharmacy Solutions’ Pharmacy Department by calling 1-800-782-2221.